UT Southwestern Medical Center has earned a place in a national clinical trials network that will make it easier to test promising treatments for patients with brain, muscle and nerve disorders.
UT Southwestern was one of just 25 sites selected for the National Institute of Neurological Disorders and Stroke’s (NINDS) new Network for Excellence in Neuroscience Clinical Trials, and is the only participating medical center in Texas and its bordering states.
The network, known as NeuroNEXT, is termed a unique model of clinical trials for brain diseases. By creating a shared infrastructure and institutional review board, institute officials said they expect to minimize the time and expense of studies while making new treatments available to patients more quickly.
Dr. Mark Goldberg, chairman of neurology and neurotherapeutics at UT Southwestern and a co-principal investigator for the project stated, "We want to bring the fruits of discovery in the laboratory as quickly as we can to the patients who need them. It is more efficient to have a well-organized team in place, allowing us to test one therapy after the next.”
UT Southwestern is expected to receive $1.4 million in NINDS support over the next seven years for its role in the network.